Related by context. All words. (Click for frequent words.) 60 TAFA# 59 eculizumab 59 Amigal 59 Augment Injectable 59 Amrubicin 58 Dacogen injection 58 belinostat 57 Panzem R NCD 57 PEG SN# 57 ISA #.#a standard 57 JAK inhibitor 57 MBP# [001] 57 NP2 Enkephalin 57 L BLP# 57 OHR/AVR# 57 IRX 2 57 liposomal formulation 56 picoplatin 56 Proxinium TM 56 glufosfamide 56 Archexin 56 OvaRex ® MAb 56 Glufosfamide 56 elotuzumab 56 Phase 2b 56 Chemophase 55 pralatrexate 55 Vernakalant 55 #D#C# 55 Traficet EN 55 Budesonide MMX 55 MOZOBIL 55 histone deacetylase HDAC inhibitor 55 CIMZIA TM 55 amrubicin 55 ponatinib 55 subcutaneous formulation 55 metaglidasen 55 pain palliation 55 Plicera 55 phase IIa clinical 55 CRMD# 55 Sym# 55 Phase 2b kidney transplant 55 Allovectin 7 ® 55 Civacir 55 Alzhemed TM 55 Phase #b/#a 54 Myocet 54 Azedra 54 OvaRex MAb 54 docetaxel Taxotere ® 54 Zerenex 54 Neuradiab 54 ISTODAX 54 PHX# 54 AeroLEF TM 54 Phase III psoriasis 54 HuMax CD4 54 Targeted Chemotherapy 54 phase IIb clinical 54 rNAPc2 54 SUTENT ® 54 oral prodrug 54 tivozanib 54 EFAPROXYN 54 Apoptone 54 ProLindac 54 aflibercept 54 relapsing multiple sclerosis 54 CBLC# 54 decitabine 54 ofatumumab 54 sapacitabine 54 FOLOTYN 54 Phase Ib clinical 54 PRX# 54 Clavis Pharma 54 MGd 54 oral taxane 54 Tarceva TM 54 OvaRex R 54 Phase III Psoriasis 54 IRESSA 54 registrational trial 53 ixabepilone 53 histamine dihydrochloride 53 HspE7 53 HQK 53 valopicitabine 53 MGCD# [001] 53 docetaxel chemotherapy 53 ASONEP 53 VELCADE 53 blinatumomab 53 MEK inhibitors 53 ARIKACE 53 Liprostin 53 YONDELIS R 53 Onco TCS 53 FOLOTYN ® 53 forodesine 53 ThermoDox R 53 Panzem R 53 Plenaxis TM 53 ISA#.#a 53 DAVANAT 53 oxymorphone ER 53 deforolimus 53 Surfaxin LS 53 obatoclax 53 Bicifadine 53 SNALP technology 53 Urocidin TM 53 personalized immunotherapy 53 favorable pharmacokinetic profile 53 BrachySil 53 KRN# 53 MGN# 53 ThermoDox ® 53 Phase Ib study 53 refractory AML 53 vidofludimus 53 ADVEXIN 53 Virulizin ® 53 Thorough QT 53 ONTAK 53 Taxotere ® 53 Vascular Wrap TM 53 Amplimexon 53 Allovectin 7 53 orBec R 53 TORISEL 53 mertansine 53 albinterferon alfa 2b 53 PrevOnco ™ 53 BrachySil TM 53 Xanafide 53 INTERCEPT platelets 53 relapsed multiple myeloma 53 AEG# 53 cilengitide 53 sipuleucel T 53 GEM OS1 53 Gemzar ® 53 IMiDs 53 tanespimycin 53 TELINTRA 53 Imprime PGG 53 Ceplene histamine dihydrochloride 53 PXD# 53 ritonavir boosted danoprevir 53 TACI Ig 53 IMA# 53 perifosine 52 Phase 2b study 52 CEQ# 52 bevacizumab Avastin ® 52 targeted radiotherapeutic 52 histone deacetylase inhibitor 52 RECOTHROM 52 custirsen 52 VAPRISOL 52 celgosivir 52 OncoVEX GM CSF 52 HuMax EGFr 52 Phase Ib II 52 neratinib 52 GRNVAC1 52 refractory chronic lymphocytic 52 HDAC Inhibitor 52 YONDELIS 52 ongoing Phase 1b 52 Trobalt 52 PLX PAD 52 vorinostat 52 CTA# Injection 52 ara C 52 IMiDs ® compound 52 vernakalant oral 52 lapatinib Tykerb 52 Hsp# Inhibitor 52 Bezielle 52 ATL# [001] 52 PROVENGE 52 BENLYSTA ® 52 Insegia 52 CA4P 52 Nanobody 52 Targretin 52 Onrigin TM 52 Virulizin R 52 ZK EPO 52 Annamycin 52 Pemetrexed 52 Cimzia TM 52 carfilzomib 52 interferon gamma 1b 52 Phase 2b trial 52 KNS # 52 tezampanel 52 RhuDex ® 52 CRLX# 52 docetaxel Taxotere R 52 standard chemotherapy regimen 52 velafermin 52 Locteron ® 52 EOquin TM 52 Soliris eculizumab 52 sunitinib malate 52 PDX pralatrexate 52 REMINYL ® 52 Evoltra ® 52 Reolysin 52 Hyphanox 52 Revlimid lenalidomide 52 ISIS # 52 TASQ 52 atacicept 52 elacytarabine 52 Quinamed 52 Phase IIa trials 52 DOS# 52 Zenvia Phase III 52 gemcitabine Gemzar ® 52 Apaziquone 52 BCIRG 52 MabCampath 52 Perifosine 52 S1P antibody 52 Fludara 51 Phase 1b clinical 51 Aryplase 51 Doxil ® 51 pharmacokinetic pharmacodynamic 51 Xcytrin 51 teriflunomide 51 synthetic retinoid 51 adecatumumab 51 enzastaurin 51 Xelox 51 vosaroxin 51 omacetaxine 51 evaluating tivozanib 51 TAXUS TM 51 Simulect 51 5 Fluorouracil 51 PrevOnco 51 rALLy clinical trial 51 XL# XL# 51 Phase Ib 51 pharmacokinetic PK study 51 Bellicum 51 confirmatory Phase III 51 phase IIb 51 refractory multiple myeloma 51 relapsed refractory multiple myeloma 51 Enzyme Replacement Therapy 51 LEUKINE 51 proteasome inhibitor 51 CD# antibody [001] 51 Catena ® 51 BEMA TM Fentanyl 51 INCB# [001] 51 MGCD# [002] 51 Dasatinib 51 Fx #A 51 Fodosine 51 Taxotere R 51 Personalized Immunotherapy 51 Vivecon 51 EndoTAG TM -1 51 CR# vcMMAE 51 Phase 1a clinical 51 R sorafenib tablets 51 gemcitabine chemotherapy 51 Onalta 51 UPLYSO 51 Azixa 51 mapatumumab 51 CD# CEA 51 teduglutide 51 ONCASPAR 51 LEP ETU 51 Onconase 51 cisplatin gemcitabine 51 huC# DM4 51 PNP inhibitor 51 eniluracil 51 GW# [003] 51 TRO# 51 forodesine hydrochloride 51 including eniluracil ADH 51 SinuNase ™ 51 sodium thiosulfate STS 51 Defibrotide 51 Phase 2b clinical trials 51 rFIXFc 51 romidepsin 51 Levacor 51 APOPTONE 51 Zenvia ™ 51 bardoxolone 51 BrachySil ™ 51 IMP# 51 pertuzumab 51 RH1 51 Azedra TM 51 Vicinium TM 51 GED aPC 51 phase IIa 51 veltuzumab 51 GATTEX TM 51 registrational 51 CoFactor 51 AzaSite Plus 51 Troxatyl 51 palifosfamide 51 trastuzumab DM1 T DM1 51 PKC# 51 Yondelis ® 51 Avastin bevacizumab 51 PRT# 51 LymphoStat B TM 51 ON #.Na 51 brivaracetam 51 Symadex 51 OncoGel 51 Phase #b/#a clinical 51 IMC A# 51 zalutumumab 51 ViRexx 51 ACTEMRA TM 51 Pirfenidone 51 vandetanib 51 TELCYTA 51 mTOR inhibitor 51 Satraplatin 51 EOquin 51 Alocrest 51 multicenter Phase II 51 Ixempra 51 rALLy trial 51 Fludara ® 51 thalidomide Thalomid 51 lintuzumab 51 Pivotal Trial 51 REOLYSIN ® 50 AQ4N 50 Aurexis 50 Kamada AAT 50 Standards Consortium CDISC 50 HCV protease inhibitor 50 Phase IIb clinical trials 50 AS# amonafide L malate 50 multicenter clinical 50 HGS ETR1 50 anticancer agent 50 Tectin TM 50 PCK# 50 oral Azacitidine 50 investigational humanized monoclonal antibody 50 Restanza 50 Phase 2a trial 50 MAGE A3 ASCI 50 alvespimycin 50 FOLFOX6 chemotherapy regimen 50 pomalidomide 50 Phase IIa clinical 50 fosbretabulin 50 Opexa 50 evaluating Xcytrin 50 refractory Hodgkin lymphoma 50 otelixizumab 50 refractory PTCL 50 ELACYT 50 Factor VIIa 50 IL# PE#QQR 50 R roscovitine 50 HGS# 50 Clolar ® 50 Phase IIa clinical trials 50 Pivotal Phase III 50 APF# 50 farletuzumab 50 lintuzumab SGN 50 Asentar 50 Vascugel 50 Aptivus ® 50 RP# [002] 50 vinca alkaloid 50 Pertuzumab 50 Marqibo 50 Stimuvax 50 Temsirolimus 50 AGGRASTAT R 50 HuMax TAC 50 Cethrin 50 NGX# 50 lesinurad 50 radiation sensitizer 50 Cloretazine ® 50 SPIRIVA HandiHaler 50 TLK# 50 Zybrestat 50 evaluating REVLIMID 50 Alpharadin 50 INCB# [002] 50 preclinically 50 L MTP PE 50 MEK inhibitor RDEA# 50 Oasmia 50 Taxotere chemotherapy 50 Locteron 50 dacetuzumab 50 Evoltra 50 sapacitabine CYC# 50 Aeroquin 50 anti CD3 monoclonal 50 EchoCRT 50 Phase III Clinical Trial 50 AZILECT R 50 brentuximab vedotin 50 Backplane Ethernet 50 ganaxolone 50 phase 2a 50 Ceflatonin 50 Blinatumomab 50 forodesine HCl 50 Chemokine Therapeutics 50 BRIM2 50 BLP# Liposome Vaccine 50 metastatic CRC 50 CCX# B 50 Daclizumab 50 biologic therapies 50 depsipeptide 50 ZACTIMA 50 PSN# [001] 50 panitumumab 50 Voreloxin 50 indibulin 50 BCR ABL inhibitor 50 G#DT 50 IAP inhibitors 50 preclinical efficacy 50 Eculizumab 50 product platforms AZX# 50 tamibarotene 50 MEND CABG II 50 satraplatin 50 Cloretazine R VNP#M 50 Advanced Renal Cell 50 Phase IIb clinical 50 Exelixis compounds 50 Phase 1b trial 50 refractory CLL 50 ALN TTR# 50 TRISENOX ® 50 XL# XL# XL# XL# 50 Sudhir Agrawal D.Phil 50 clevidipine 50 ATACAND 50 TARIS 50 Genasense ® oblimersen 50 zanolimumab 50 oral antiviral 50 Acute Ischemic Stroke 50 voreloxin 50 RG# [001] 50 peginesatide 50 VPRIV 50 Phase 2a clinical trials 50 drug GAP #B# 50 TREANDA 50 rxRNA 50 GRN#L 50 tiapamil 50 sorafenib tablets 50 R#/MEM # 50 encapsulates siRNAs 50 riociguat 50 receptor tyrosine kinase inhibitor 50 NVA# 50 Indaflex TM 50 Nexavar ® 50 FavId 49 Pazopanib 49 Tesetaxel 49 monoclonal anti 49 LymphoStat B 49 Mitoxantrone 49 Vilazodone 49 eltrombopag 49 Omacetaxine 49 Ceflatonin R 49 REG2 49 Ketotransdel 49 CUSTOM III 49 Poly ICR 49 investigational monoclonal antibody 49 cancer immunotherapies 49 EGFR HER2 49 NCCTG 49 GLP toxicology studies 49 PROCHYMAL 49 MabVax 49 velafermin belinostat 49 CG# [003] 49 Androxal TM 49 LibiGel Phase III 49 humanized anti 49 JAK1 49 multiple myeloma MM 49 afatinib 49 CYT# potent vascular disrupting 49 atrasentan 49 Syndax 49 TNFerade 49 CORT # 49 ECTRIMS 49 carboplatin paclitaxel 49 paclitaxel Taxol ® 49 Chrysalin 49 WILEX 49 investigational therapies 49 novel histone deacetylase 49 CorVue ™ 49 PI3K/Akt pathway inhibitor 49 nab paclitaxel 49 PROSTVAC TM 49 liposome formulations 49 ATIR 49 phase IIb III 49 Golimumab 49 CLARITY study 49 lenalidomide Revlimid R 49 2 methoxyestradiol 49 BiovaxID 49 BCX# 49 oncology indications 49 anticancer compound 49 Tarvacin TM 49 dose cohort 49 ALN PCS 49 talactoferrin 49 tolerability profiles 49 ZYBRESTAT 49 vascular disrupting agent 49 Viramidine 49 Elotuzumab 49 ERBITUX 49 AP# [003] 49 DAVANAT R 49 Phase IIIb clinical 49 pegloticase 49 myeloproliferative disorders 49 neoadjuvant treatment 49 ASGT 49 ARIXTRA 49 hormone LHRH antagonist 49 AVE# 49 BioNumerik 49 Bortezomib 49 orBec ® 49 EXPAREL ™ 49 oral ridaforolimus 49 GATTEX 49 DermaVir Patch 49 docetaxel Taxotere 49 Urocortin 2 49 mocetinostat MGCD# 49 IgG1 monoclonal antibody 49 NSABP 49 Telatinib 49 ALN TTR 49 galiximab 49 Treanda 49 Phase IIB 49 EORTC 49 elesclomol 49 seliciclib CYC# 49 #I TM# 49 XmAb# 49 HDL Selective Delipidation 49 Gliadel Wafer 49 fallopian tube cancers 49 AS# [003] 49 AEterna 49 PROPEL 49 PSMA ADC 49 Velcade bortezomib 49 PhotoCure 49 SAR# [004] 49 pharmacokinetic PK 49 ENMD # 49 nonclinical studies 49 Phase III confirmatory 49 lupus nephritis 49 tramiprosate Alzhemed TM 49 Genasense 49 Celator 49 AzaSite Xtra 49 Phase 1b 49 antibody MAb 49 Onrigin 49 CYT# 49 tasocitinib 49 Clinical Oncology ASCO Annual 49 CALGB # [002] 49 vismodegib 49 Gleevec imatinib mesylate 49 XL# [003] 49 Granted Orphan Drug 49 ImmuKnow R 49 DP b# 49 tezampanel NGX# 49 AKT inhibitor 49 assessing T DM1 49 Amphinex ® 49 HCD# [002] 49 OMAPRO 49 TASKi3 49 GORE TAG Device 49 CCX# 49 trabectedin 49 Romiplostim 49 brentuximab vedotin SGN 49 pharmacological chaperone 49 metastatic HRPC 49 EGRIFTA TM 49 HepaSphere 49 urocortin 2 49 ADVEXIN clinical 49 ToGA 49 pharmacokinetic characteristics 49 Neulasta ® 49 phase Ib 49 Platinol ® cisplatin 49 Triapine 49 ISHLT 49 XL# XL# XL# 49 Phase 2a clinical 48 maximally tolerated dose 48 Panzem 48 TQT studies 48 OXi# 48 solid organ transplantation 48 Hsp# inhibitor 48 Tyrima 48 Bendavia 48 CD# monoclonal antibody 48 WirelessHART 48 DAVANAT ® 48 StemEx R 48 GVAX immunotherapy 48 QTinno TM 48 Phase 2a 48 RITUXAN 48 Phase III 48 Darinaparsin 48 bortezomib Velcade 48 Bendamustine 48 AAG geldanamycin analog 48 metastatic renal cell carcinoma 48 TYKERB 48 low dose cytarabine 48 SUCCEED trial 48 alfa 2a 48 plus dexamethasone 48 ganetespib 48 Stimuvax R 48 Pralatrexate 48 Clinical Oncology Annual Meeting 48 SU# [003] 48 TRAIL receptor antibodies 48 targeting CD# 48 Vidaza 48 Ambrisentan 48 Dr. Yatscoff 48 bevacizumab Avastin 48 ISTODAX ® 48 cutaneous T cell 48 investigational immunotherapy 48 refractory acute myeloid 48 axitinib 48 OPAXIO 48 thymalfasin 48 Inflazyme 48 SPIRIT Consortium 48 gemcitabine cisplatin 48 BiTE antibody 48 Tamibarotene 48 AACR NCI EORTC 48 Hepatocellular Carcinoma HCC 48 GVAX R 48 GlycoPEG GCSF 48 PLK1 SNALP 48 Orazol 48 Initiate Phase II 48 oral JAK#/JAK# inhibitor 48 Arno Therapeutics 48 Cloretazine 48 AERx iDMS 48 Phase 2b clinical 48 TOCOSOL Paclitaxel 48 AGGRASTAT ® 48 PRIALT 48 Hematology Meeting 48 selective adenosine 48 kidney urologic 48 ZEVALIN ® 48 entinostat 48 cediranib 48 HuMax 48 Aggrastat ® tirofiban hydrochloride 48 clofarabine 48 TASKi2 48 NanoCrystal technology 48 GTC recombinant human 48 MAXY G# 48 BioMarck 48 pegylated interferon alfa 2b 48 randomized controlled Phase 48 demonstrated antitumor activity 48 Zarnestra 48 PS# [001] 48 Curaxin 48 mRCC 48 Aflibercept 48 chemoradiotherapy 48 docetaxel 48 briakinumab 48 ABRAXANE 48 BNC# 48 lymphoma CTCL 48 BCG refractory 48 trastuzumab Herceptin 48 Cardiology ESC 48 ALN HPN 48 Tovaxin 48 PhG alpha 1 48 DSMB 48 Hemospan 48 MyVax R 48 ridaforolimus 48 NEUMUNE 48 AspenBio 48 TriGrid ™ 48 Selective Electrochemical Tumor Ablation 48 UVIDEM 48 anti angiogenic agents 48 ARRY # 48 randomized Phase IIb 48 HRPC 48 FRDA 48 sorafenib Nexavar 48 pan HDAC inhibitor 48 NCCN guidelines 48 Poly ICLC 48 cintredekin besudotox 48 bortezomib Velcade R 48 oral deforolimus 48 confirmatory Phase 3 48 Chemokine 48 PANVAC VF 48 GALNS 48 cancer neuroendocrine tumor 48 CAMPATH 48 Squalamine 48 Investigational Drug 48 Amorcyte 48 XL# anticancer compounds 48 HGS ETR2 48 chemotherapeutics 48 Endeavor DES 48 novel VDA molecule 48 Viprinex 48 Phase #/#a trial 48 samalizumab 48 adecatumumab MT# 48 ASA# 48 CINTREDEKIN BESUDOTOX 48 plerixafor 48 Guanilib 48 ® bortezomib 48 dose cohorts 48 MEPACT 48 CBLB# 48 placebo controlled clinical 48 tesmilifene 48 epoetin beta 48 Aloxi injection 48 Romidepsin 48 Solazed TM 48 Phase III clinical 48 ANA# 48 DCVax ® Brain 48 HGS ETR1 mapatumumab 48 adult chronic ITP 48 REVLIMID 48 Triolex 48 JIL widget 48 vinorelbine tartrate 48 Zemiva TM 48 MEND CABG 48 Cintredekin Besudotox 48 ZYBRESTAT fosbretabulin 48 Cotara 48 oral proteasome inhibitor 48 atypical Hemolytic Uremic Syndrome 48 Cutaneous T 48 Homspera 48 ORTHOCON 48 PEG Interferon lambda 48 CardioFit 48 lumiliximab 47 Multikine 47 rindopepimut 47 Oncaspar 47 anticancer therapy 47 Vandetanib 47 migalastat HCl 47 MyVax ® 47 lorvotuzumab mertansine 47 erlotinib Tarceva ® 47 Kahalalide F 47 ProSavin 47 beta 1a 47 phase IIb study 47 IMC #B 47 EDEMA3 47 MorphoSys proprietary 47 Phase III HEAT 47 JAK2 inhibitor 47 imetelstat 47 randomized Phase 2b 47 Leukine ® 47 IAP inhibitor 47 ASCO GI 47 Delcath PHP System 47 Phase III Trials 47 telomerase therapeutic 47 ANTEGREN 47 Virium 47 TroVax 47 Cancers Symposium 47 Protexia R 47 ANSI C#.# 47 Ocrelizumab 47 tesetaxel 47 PEGylated interferon beta 1a 47 ApoB SNALP 47 Intravenous CP 47 BioSTAR ® 47 MacuSight 47 reteplase 47 EndoTAGTM 1 47 ReN# 47 pemetrexed Alimta 47 Anturol 47 Manja Bouman CEO 47 Arginox 47 REOLYSIN R 47 THR beta agonist 47 PolyActive ® 47 AVAX 47 conformance testing 47 Nitec 47 Elan NanoCrystal 47 ISTH 47 DASISION 47 Phase 2a Clinical Trial 47 Avicena 47 ThermoDox 47 antiangiogenic therapy 47 PEGPH# 47 Folotyn 47 TAXUS ATLAS 47 Aerosurf 47 recurrent NSCLC 47 stable angina 47 dacetuzumab SGN 47 TOPIGEN 47 orally administered inhibitor 47 drug conjugate 47 tolerability pharmacokinetics 47 tubulin inhibitor 47 BR.# 47 Aegera 47 prucalopride 47 pradefovir 47 proteasome inhibitors 47 omega interferon 47 Synavive 47 TRISENOX 47 alemtuzumab Campath 47 Junovan TM 47 Certican 47 microsphere therapy 47 paclitaxel poliglumex 47 Exherin TM 47 Allovectin 7 R 47 OMP #M# 47 Nexavar sorafenib 47 Carfilzomib 47 Denufosol 47 sunitinib 47 LonMark 47 SCTE 47 Natalizumab 47 Interferon alpha 47 Hedgehog antagonist 47 advanced carcinoid 47 HIF PHI 47 ACCLAIM II 47 ISA SP# [002] 47 hyaluronidase rHuPH# 47 MAXY alpha 47 VEGF Trap 47 UHF Generation 47 Cimzia ® certolizumab pegol 47 anticancer therapies 47 anti CD# antibodies 47 BiovaxID TM 47 LUMINATE 47 R bortezomib 47 Tesmilifene 47 Boceprevir 47 Orphan Designation 47 NTDDS 47 Intarcia 47 BiTE R 47 DPX Survivac 47 pivotal Phase III 47 ATryn R 47 GPIIb IIIa 47 Ontak 47 randomized Phase 47 Genasense R 47 Xcellerated T Cells 47 BENICAR 47 torezolid phosphate 47 C1 INH 47 Voraxaze ™ 47 OncoVEX 47 recombinant FVIII 47 allogeneic stem cell 47 mitogen activated ERK kinase 47 oral picoplatin 47 XL# SAR# 47 NN# [001] 47 recurrent glioma 47 Intravenous Human 47 Jevtana 47 STEDESA 47 Protectan CBLB# 47 BEMA Buprenorphine 47 EGS# 47 Ramoplanin 47 Phase IIb trials 47 Belinostat 47 gefitinib 47 trastuzumab Herceptin R 47 subcutaneous SC 47 Endoscopic Ablation System 47 IFN Beta CTP 47 PSN# [002] 47 papillary renal cell carcinoma 47 Tocosol Paclitaxel 47 Ruconest 47 Genasense ® 47 seliciclib 47 RapidIO specification 47 Transdel TM 47 QTinno 47 anticancer agents 47 Proellex TM 47 eritoran 47 bardoxolone methyl 47 Xeloda ® 47 Phase 1b clinical trials 47 Hedgehog Pathway Inhibitor 47 GAP #B# 47 Podium Presentation 47 CONBRIZA 47 NEUVENGE 47 RTOG 47 evaluating satraplatin 47 Breast Surgeons ASBS 47 SparVax TM 47 SYN# 47 PERSEUS 47 Exherin 46 IoGen 46 darinaparsin ZIO 46 epoetin alpha 46 Angiox R 46 ipilimumab